By Industry News
Toronto, Canada – February 10, 2020 – University Hospitals Ahuja Medical Center (UH) is the first clinical setting in Ohio using special technology to identify harmful bacteria, leading to healing for patients suffering from chronic wounds.
Windy Cole, DPM, Medical Director of the UH Ahuja Wound Care Center, conducted research studies utilizing the MolecuLight i:X® and is leading the use of the novel device in the state.
"A violet light is shone onto the area of the wound, and it excites bacteria on the surface," Dr. Cole explained. "In real-time, different types of bacteria fluoresce different colors, so we can tell if and where tissues have certain bacteria levels. The i:X device can detect bacteria at loads that delay wound healing and go undetected with standard of care wound assessment. This means we're now able to see what's happening on and below the surface of these wounds, beyond the naked eye and before problems arise."
Patients with diabetes or poor circulation can develop chronic wounds that do not heal over weeks, months or even years. These wounds are susceptible to infection causing pain for the patient and greatly impacting their quality of life. Patients may need IV antibiotics, hospitalization, surgery, or worst case, amputation. Preventing the spread of infection is key in order to improve mobility and avoid amputation.
"Most often, patients we're seeing in the wound care center are those with chronic wounds," said Dr. Cole. "We consider chronic wounds to be those that have been open for longer than four weeks. Many of our patients have been through trauma or have systemic diseases such as diabetes, peripheral arterial disease or peripheral vascular disease that make the healing process very slow."
The MolecuLight i:X received FDA de novo clearance in August 2018 and then 510(k) clearance in December 2019, and Dr. Cole is currently using the device in her clinical practice.
To learn more about Dr. Cole’s practice and the MolecuLight i:X imaging procedure, view the following video.
About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 50 health centers and outpatient facilities, and 200 physician offices in 16 counties throughout northern Ohio.
About MolecuLight Inc.
MolecuLight Inc. (www.moleculight.com) is a privately owned Canadian medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical and commercial markets. MolecuLight’s initial product, the MolecuLight i:X®, and its accessories delivers a real-time handheld fluorescence imaging solution for the global wound care market. The MolecuLight i:X provides clinicians with information about the fluorescent characteristics of wounds to assist clinicians in making improved diagnostic and treatment decisions. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.